Budapest, Hungary

Janos Sagi


Average Co-Inventor Count = 10.4

ph-index = 2

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 1984-1998

Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Janos Sagi

Introduction

Janos Sagi is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of biotechnology, particularly in the development of oligonucleotides and methods for treating viral infections. With a total of 5 patents to his name, Sagi's work has had a meaningful impact on medical science.

Latest Patents

Among his latest patents, Sagi has developed oligodeoxynucleotides that contain various 5-substituted uracil or cytosine. This innovation includes a 12 to 30 nucleotide-unit long oligonucleotide that features a 5-substituent, which can be a C.sub.3-6 n-alkyl, a vinyl, a butenyl, an ethynyl, or a C.sub.4-12 n-1-alkynyl. Importantly, the uracil moiety is not allowed to be substituted with an n-alkyl or a C.sub.8-12 n-1-alkynyl. Additionally, he has patented a method for treating herpes eye infections using an ophthalmic composition that comprises 5-propyl-2'-deoxyuridine.

Career Highlights

Janos Sagi has worked with several prominent organizations throughout his career. Notably, he has been associated with the MTA Zozponti Kemiai Kutato Intezet and Egyt Gyogyszervegyeszeti Gyar. His work in these institutions has allowed him to advance his research and contribute to significant scientific advancements.

Collaborations

Sagi has collaborated with various professionals in his field, including Attila Szemzo and Anna Szabolcs Nee Borbas. These collaborations have enriched his research and expanded the scope of his inventions.

Conclusion

Janos Sagi's innovative contributions to biotechnology and his dedication to research have established him as a prominent figure in his field. His patents and collaborations reflect his commitment to advancing medical science and improving treatment options for viral infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…